Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 18, 2025PLoS ONEOpen Access

Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJia SongYKYan KangLWLina Wang

Discussion

Loading...

Member takes

Overview

Observational analysis found that finerenone reduces urinary protein levels in DKD patients, highlighting its potential role in managing inflammation.

Key Points

  • Finerenone treatment significantly reduced urinary protein levels in patients with diabetic kidney disease, leading to improved renal outcomes.
  • After 6 months of treatment, the macroalbuminuria group saw greater decreases in urinary protein compared to the microalbuminuria group.
  • This was an observational study with 48 DKD patients treated for 6 months, collecting various renal and inflammatory markers.
  • Finerenone shows promising safety and efficacy, particularly for patients with macroalbuminuria needing kidney protection.

Cite This Study

Song et al. (2025) studied this question.

synapsesocial.com/papers/68af33efcf1dd9ea359e9577https://doi.org/10.1371/journal.pone.0329965
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China2025
  2. 2Real-World Impact of Finerenone on Albuminuria in Patients with Diabetes and CKD2025
  3. 3Evaluating the Efficacy of Finerenone in Reducing Proteinuria in Diabetic Nephropathy Patients Receiving Maximum Tolerable Doses of Dapagliflozin and Telmisartan2025
  4. 4Efficacy and Safety of Finerenone for Renal and Cardiovascular Events in DiabeticKidney Disease: A Meta-analysis2026
  5. 51403-P: Effects of Finerenone on Chronic Kidney Disease in Patients with Type 2 Diabetes: Association with Metabolic Dysfunction–Associated Steatotic Liver Disease2026